Intelligent Synthetic Biology Center

Korea Advanced Institute of Science and Technology

Korea Research Institute of Bioscience and Biotechnology

Scarab Genomics, LLC

Sun Chang Kim

Wan Taek Im

So Yeon Kim

Choong Hoon Lee

Chang Hao Cui

Bong Hyun Sung

Chan Bae Park

Suk Chae Jung

Ju Ri Shin

Su A Jang

Hun Sik Kim

Frederick R Blattner

Ju Young Lee

Gou Young Koh

Myung Ho Kim

Jin Hee Han

Sang Kyu Lee

Won Do Heo

Da Jung Kim

Woo Hyun Kim

Bong Hwan Park

Gyun Min Lee

Jun Hyoung Lee

Ki Jun Jeong

Young Woong Lee

Ho Min Kim

Ki Jung Lim

Yoon Hyeok Lee

Young Jun Koh

Myung Keun Park

Keehoon Jung

Gil Tsu Choi

Sang Hee Lee

In Yup Park

Song Gun Kim

Ki Jeong Lim

Won Il Jeong

Soon Jang Lee

Jong Min Jeong

Hyun Bae Bang

Hyung Gwan Lee

Ji In Kang

Kyung Seok Yang

Sung Taik Lee

Jung Min Kim

Dong Shan An

Soo Hwan Lim

Byung Jo Yu

Kui Hyeon Kang

Yeon Lee

Won Ii Jeong

Ju Yeon Jung

The present invention relates to compositions for enhancing innate immunity, comprising ginsenoside F1 as an active ingredient. Specifically, the composition according to the present invention promotes degranulation activity and cell-killing activity of natural killer cells, and increases expressions of cell-killing factors, thereby being effectively used as an innate immunity enhancer.

Method for enhancing immunity using ginsenoside F1 as an active ingredient

Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.

Composition for preventing or treating cervical cancer including gypenoside LXXV

The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Composition for preventing or treating vascular leak syndrome

The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside R3 as an active ingredient

The present invention relates to a method for screening an activator of mitochondrial activity by using gypenoside-treated cells, to a composition for screening an activator of mitochondrial activity, comprising the gypenoside, and to a kit comprising the composition. By using the method for screening an activator of mitochondrial activity of the present invention, it is possible to effectively discover a preparation which can substantially promote the mitochondrial activity, and thus the method is expected to be widely used in developing a therapeutic agent for diseases caused by mitochondrial activity inhibition.

Method for screening activator of mitochondrial activity

Provided are a food composition and a feed composition for removing amyloid plaques, each composition including ginsenoside F1, in which ginsenoside F1 is effective for removing amyloid plaques in the hippocampal area of the brain.

Composition containing ginsenoside F1 for removing amyloid plaques

Provided is a method of preparing cinnamaldehyde by using a recombinant microorganism.

Method of preparing cinnamaldehyde

The present invention relates to a uridine diphosphate (UDP)-glycosyltransferase protein which has glycosylation activity for a hydroxyl group at the C-20 position of a protopanaxadiol (PPD)- or protopanaxatriol (PPT)-type ginsenoside, and a method for glycosylation of UDP using the same.

Method for glycosylation of ginsenoside using a glycosyltransferase derived from panax ginseng

The present invention relates to a composition for preventing or treating liver cancer containing ginsenoside F2 as an active ingredient. Specifically, the composition according to the present invention kills liver cancer cells, specifically inhibits the formation of liver cancer, and reduces the expression of alanine aminotransferase (ALT) or aspartate aminotransferase (AST), without affecting normal hepatocytes, and thus can be usefully used as a therapeutic agent for liver cancer.

Composition for preventing or treating liver cancer containing ginsenoside F2

Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from asp. () microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

Method for producing a minor ginsenoside using a ginsenoside glycosidase

For efficient analysis of a protein-protein interaction, the present disclosure provides a kit for analyzing a protein-protein interaction, the kit including: a 1expression vector including a 1polynucleotide and a multi-cloning site, wherein, the 1polynucleotide is operably linked to a promoter and encodes a 1fusion protein having a 1fluorescence protein and a 1self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a bait protein may be operably linked to the polynucleotide encoding the 1fusion protein; and a 2expression vector including a 2polynucleotide and a multi-cloning site, wherein, the 2polynucleotide is operably linked to a promoter and encodes a 2fusion protein having a 2fluorescence protein and a 2self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a prey protein may be operably linked to the polynucleotide encoding the 2fusion protein.

Method and kit for analyzing protein-protein interaction using nanocluster formation

The present invention relates a prophylactic or therapeutic composition for cancer, and more particularly, to a prophylactic or therapeutic composition for cancer comprising a peptide which is represented by an amino acid sequence of the following Formula (I), a method for preventing or treating cancer comprising the step of administering the peptide to a subject, and use of the peptide in the preparation of the prophylactic or therapeutic composition for cancer. (I) APKAMXLLXXL-LXLQKKGI wherein X, X, Xand Xare each independently R or K.

Anticancer agents comprising peptides with cancer-specific toxicity

The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.

Fusion protein capable of binding VEGF-A and TNF-alpha

The present invention relates to a novel ginsenoside glycosidase protein derived from the genus, the protein having an activity of converting protopanaxadiol (PPD)-type saponins into highly active substances, which can be absorbed inside the body, by selective hydrolysis of a particular bond of ginsenoside. More specifically, the present invention relates to an amino acid sequence of the protein, a nucleic acid sequence encoding the protein, a recombinant vector comprising the nucleic acid sequence, and a transformant transformed with the vector, and a method for producing ginsenoside glycosidase derived from the genusby culturing the transformant, a method for converting PPD-type major saponins into the minor saponin forms using the protein, and a composition for converting PPD-type saponins into soluble saponins, comprising the protein as an active component.

[object Object]

The present invention relates generally to compositions and methods useful for, inter alia, production of commercial biologic products such as amino acids. More specifically, the present invention relates to genetically modified strains of microorganisms and the use thereof for the production of commercial products. The present invention also provides, inter alia, novel isolated DNA, nucleic acid, vectors and reduced genome bacteria.

Compositions and methods for amino acid biosynthesis

Growing community of inventors

Daejeon, South Korea

Sun Chang Kim